Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01701076
Other study ID # CTU10.041/BRd
Secondary ID 2010-022253-42
Status Completed
Phase Phase 2
First received September 27, 2012
Last updated August 23, 2016
Start date March 2012
Est. completion date February 2016

Study information

Verified date August 2016
Source Cantonal Hospital of St. Gallen
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical DevicesSwitzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

Almost all patients with multiple myeloma who survive initial treatment will eventually relapse and require further therapy.

Background: Treatment with lenalidomide and dexamethasone has proven efficacy in two large randomized trials (MM-009 and MM-010) leading to a time to progression (TTP) of 17.1 months for patients with only one prior therapy and a TTP of 10.6 months for 2 and more prior therapies, respectively [1-3]. Continuous treatment with lenalidomide and dexamethasone until disease progression is therefore considered a standard therapy for second line treatment in multiple myeloma patients. However, only a relatively low rate of high quality response (CR, complete response and VGPR, very good partial response) is achieved. High quality responses are associated with with improved progression-free survival and overall survival [4].

Trial: The aim of this trial is to improve high quality response rates for patients with relapsed or refractory multiple myeloma in the 2nd line treatment. This aim shall be achieved by the addition a third anti-myeloma drug (bendamustine) to the established backbone of lenalidomide/ dexamethasone.

Treatment regimen:

- Induction Treatment Phase: Cycles 1-6 Bendamustine 75mg/m2/d day 1 and 2, lenalidomide 25mg/d 1-21, dexamethasone 40mg / 20mg (for patients > 75years) d 1, 8, 15, 22.

- Maintenance Treatment Phase: Cycles 7-18 lenalidomide 25mg/d 1-21, dexamethasone 40mg / 20mg (for patients > 75 years) d 1, 8, 15, 22.

Due to hematoxicity of bendamustine and lenalidomide, administration of pegfilgrastim is mandatory in the induction treatment phase (BRd-regimen)for all patients experiencing severe neutropenia.

The aim of this study is to achieve high quality response rates (CR, VGPR) of ≥ 40%. If this aim is achieved, the treatment of bendamustine in combination with the established lenalidomide/ dexamethasone regimen will be considered promising.

Besides efficacy, the safety of this three-drug regimen is evaluated in this trial.


Description:

Assessments for efficacy / response evaluation:

- M-protein quantitation in serum and 24 h urine collection samples by serum- and urine protein electrophoresis

- Quantitation of immunoglobulin levels by nephelometry

- Serum and urine immunofixation

- Free light chain concentrations and ratio in the serum

- Plasma cell percentage in the bone marrow by conventional cytology and biopsy with immunohistochemistry

- Radiologic assessments of the skeleton

Response criteria: Response will be assessed according to IMWG criteria


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Written informed consent

- Patients with first relapsed or refractory multiple myeloma (including patients with relapse after high dose chemotherapy followed by autologous stem cell transplantation) who have received no more than one prior line of anti-myeloma treatment

- Treatment with a lenalidomide/ dexamethasone-based 2nd-line regimen is indicated and intended

- Measurable disease as defined by at least one of the following 3 measurements

- serum monoclonal protein level = 1 g/dl (= 10 g/l) or

- urine M-protein level = 200 mg/24hours or

- serum FLC assay: Involved FLC level = 10 mg/dl (= 100 mg/l) provided serum FLC ratio is abnormal

- ECOG performance status 0, 1, or 2

- Age = 18 years

- All previous cancer therapy (except corticosteroid therapy), including radiation, cytostatic therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.

- No prior treatment with a bendamustine-containing regimen allowed

- Prior treatment with lenalidomide is allowed if the treatment is completed > 12 month prior to study entry and the patient responded to prior lenalidomide treatment

- Adequate hematological values:

- absolute neutrophil count = 1.5 x 109/L

- platelets = 100 x 109/L

- hemoglobin > 80 g/L, unless considered to be caused by the underlying hematologic malignancy, based on the investigator's clinical judgement

- Adequate hepatic function:

- total bilirubin < 1.2 mg/dL

- AST (SGOT) = 2.5 x ULN

- Adequate renal function:

o calculated creatinine clearance > 50 ml/min, according to the formula of Cockcroft-Gault

- Disease free of prior malignancies for > 5 years unless the patient

- has been treated with a curative intent and is considered to be in complete remission for =2 years prior to study enrolment

- or has a curatively-treated

- basal cell/ squamous cell carcinoma of the skin,

- carcinoma "in situ"of the cervix,

- ductal breast carcinoma in situ with complete surgical resection (i.e. negative margins),

- medullary or papillary thyroid tumor

- or low grade, early stage localized prostate cancer treated surgically with curative intent

Exclusion Criteria:

- Pregnant or breast feeding females

- Any prior use of bendamustine

- Patients who are unable or unwillingly to undergo antithrombotic therapy

- Any serious underlying medical condition (at the judgment of the investigator) which impairs the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorder)

- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she would participate in the study or any condition significantly confounding the ability to interpret data from the study, based on the local investigator's judgement

- Severe cardiovascular disease, including myocardial infarction within 6 months before study entry, New York Heart Association Class III or IV heart failure, uncontrolled angina or severe uncontrolled ventricular arrhythmias (= Lown 3)

- Use of any other experimental drug or therapy/ treatment in a clinical trial within 30 days prior to trial entry

- Known hypersensitivity to study drug(s) or hypersensitivity to any other component of the study drugs

- Any concurrent antineoplastic therapy with chemotherapeutic agents or biologic agents or radiation therapy

- Any major surgical procedure within 30 days prior to study therapy

- Known chronic hepatitis B or C, known HIV infection

- Jaundice or any other severe damage of the liver parenchyma

- Any contraindication for the treatment with bendamustine, lenalidomide, dexamethasone and / or pegfilgrastim in accordance with the appropriate SmPCs

- Any other concomitant drugs contraindicated for use with the study drugs according to the national health authorities

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Bendamustine
Induction treatment phase (cycle 1-6): Bendamustine 75 mg/m2 i.v day 1 and 2 Lenalidomide 25 mg p.o. day 1-21 Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22 Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia Maintenance treatment phase (cycles 7-18): Lenalidomide 25 mg p.o. day 1-21 Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22

Locations

Country Name City State
Switzerland Kantonsspital St. Gallen St. Gallen

Sponsors (5)

Lead Sponsor Collaborator
Cantonal Hospital of St. Gallen Amgen, Celgene Corporation, Mundipharma Medical Company, Mundipharma Research GmbH & Co KG

Country where clinical trial is conducted

Switzerland, 

References & Publications (6)

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544. — View Citation

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. doi: 10.1038/leu.2009.147. Epub 2009 Jul 23. — View Citation

Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009 Oct 8;114(15):3139-46. doi: 10.1182/blood-2009-03-201053. Epub 2009 Jul 28. Review. — View Citation

Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012 May 17;119(20):4608-13. doi: 10.1182/blood-2011-12-395715. Epub 2012 Mar 26. — View Citation

Pönisch W, Heyn S, Wagner I, et al. Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial. Blood, Nov 2010; 116: 1971

Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen Every 4 weeks up to 7 months No
Secondary Objective response rates (sCR, CR, VGPR, PR, MR) Every 4 weeks up to 7 months No
Secondary Best response (sCR, CR, VGPR, PR, MR) Every 4 weeks up to 36 months No
Secondary Time to progression (TTP) Every 4 weeks up to 36 months No
Secondary Overall survival (OS) Every 8 weeks up to 36 months No
Secondary Safety and tolerability Type, frequency, severity, and relationship of adverse events to study therapy
According to NCI CTCAE v4.0
Every 4 weeks until 30 days after completion of study treatment Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1